Hepatitis C Recombination Incidence and Prevalence
丙型肝炎重组发生率和患病率
基本信息
- 批准号:6743004
- 负责人:
- 金额:$ 16.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-30 至 2005-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The purpose of this R21 application is to study HCV recombination, or the exchange of genetic material resulting in hybrid genomes. For HIV-1, recombination was obscure until 1994 but is now recognized as a major mode of genetic diversification, representing an important mechanism for immune evasion and drug resistance. Recently, the first evidence of recombination in HCV was reported in specimens from St. Petersburg, Russia. To date, no other recombinant HCV genomes have been described. Because most studies of HCV genetic sequence have involved small amplicons, whereas identification of a recombinant strain requires examination of multiple genomic regions, we hypothesize that HCV recombination is a more common phenomenon than currently appreciated, and propose initial studies of its frequency and character. We have assembled a large repository of specimens for which genotype has been determined at by sequence analysis of the E1 gene. These specimens have been obtained from infected individuals in 4 U.S. cities where genotypes 1, 2, and 3 predominate, as well as Thailand where genotypes 1, 3, and 6 predominate. We also describe initial investigations of a mixed infection, containing two distinct populations of HCV, which suggest the presence of recombination. Building on years of experience investigating HIV-1 recombination, HCV sequence variation, and the genetic epidemiology of diverse HCV subtypes in Egypt, we propose to examine our repository for evidence of recombination in HCV. The goal of this application is to determine whether genetic recombinant HCV is prevalent, and to performed detailed analysis of recombinant genomes. Specifically, we aim to: (1) identify specimens with discordant genotypes at separate HCV loci, (2) examine specimens containing more than one strain to detect incident recombination, and (3) characterize putative recombinant genomes in detail. Our repository includes well-characterized longitudinally- acquired specimens and we are applying methods for which we have established expertise; therefore, this application has a high likelihood of success. Because the impact of HCV recombination has not yet been determined, R21 funding will provide adequate preliminary data to establish the importance and proper conduct of more extensive investigations.
描述(由申请人提供):本R21申请的目的是研究HCV重组,或交换导致杂交基因组的遗传物质。对于HIV-1,直到1994年,重组还不为人所知,但现在被认为是遗传多样化的主要模式,代表了免疫逃避和耐药性的重要机制。最近,在俄罗斯圣彼得堡的标本中报告了丙型肝炎病毒重组的第一个证据。迄今为止,没有其他重组HCV基因组被描述。由于大多数HCV基因序列的研究涉及小扩增子,而重组菌株的鉴定需要检查多个基因组区域,我们假设HCV重组是一种比目前所认识的更普遍的现象,并建议对其频率和特征进行初步研究。我们收集了大量的标本,通过对E1基因的序列分析确定了它们的基因型。这些标本是从基因型1、2和3为主的4个美国城市以及基因型1、3和6为主的泰国的感染者中获得的。我们还描述了混合感染的初步调查,其中包含两种不同的HCV人群,这表明存在重组。基于多年来在埃及调查HIV-1重组、HCV序列变异和各种HCV亚型遗传流行病学的经验,我们建议检查我们的存储库,寻找HCV重组的证据。该应用程序的目的是确定基因重组HCV是否普遍存在,并对重组基因组进行详细分析。具体来说,我们的目标是:(1)在不同的HCV基因座上鉴定不一致的基因型标本,(2)检查含有多个菌株的标本以检测事件重组,(3)详细表征推定的重组基因组。我们的储存库包括具有良好特征的纵向获得的标本,我们正在应用我们已经建立的专业知识的方法;因此,此应用程序成功的可能性很高。由于丙型肝炎病毒重组的影响尚未确定,R21资助将提供充分的初步数据,以确定更广泛调查的重要性和适当进行。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STUART C RAY其他文献
STUART C RAY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STUART C RAY', 18)}}的其他基金
Humoral Immune Response to Acute HCV Infection
对急性 HCV 感染的体液免疫反应
- 批准号:
7919768 - 财政年份:2010
- 资助金额:
$ 16.35万 - 项目类别:
Mechanisms driving breadth of HCV neutralization during repeated control of acute infection in humans
在反复控制人类急性感染期间推动 HCV 中和广度的机制
- 批准号:
9098152 - 财政年份:2010
- 资助金额:
$ 16.35万 - 项目类别:
Hepatitis C Recombination Incidence and Prevalence
丙型肝炎重组发生率和患病率
- 批准号:
6806549 - 财政年份:2003
- 资助金额:
$ 16.35万 - 项目类别:
SEQUENCE SELECTION AND PERSISTENCE OF HEPATITIS C
丙型肝炎的序列选择和持续性
- 批准号:
6650151 - 财政年份:1999
- 资助金额:
$ 16.35万 - 项目类别:
相似海外基金
The 13th Canadian Symposium on Hepatitis C Virus (CSHCV)
第13届加拿大丙型肝炎病毒研讨会(CSHCV)
- 批准号:
487828 - 财政年份:2023
- 资助金额:
$ 16.35万 - 项目类别:
Miscellaneous Programs
Characterization of key aspects of a controlled human infection model (CHIM) for hepatitis C virus (HCV) infection
丙型肝炎病毒 (HCV) 感染受控人类感染模型 (CHIM) 关键方面的表征
- 批准号:
478700 - 财政年份:2023
- 资助金额:
$ 16.35万 - 项目类别:
Operating Grants
After the Cure: Measuring the full impacts of direct-acting antivirals for people living with HIV/hepatitis C virus coinfection in Canada
治愈之后:衡量直接作用抗病毒药物对加拿大艾滋病毒/丙型肝炎病毒合并感染者的全面影响
- 批准号:
469805 - 财政年份:2022
- 资助金额:
$ 16.35万 - 项目类别:
Operating Grants
Perinatal care as a venue to reduce opioid overdoses and hepatitis C virus incidence (PreVenT OD HCV)
围产期护理是减少阿片类药物过量和丙型肝炎病毒发病率 (PreVenT OD HCV) 的场所
- 批准号:
10449670 - 财政年份:2022
- 资助金额:
$ 16.35万 - 项目类别:
A Simple at-home test for rapid and accurate screening for Hepatitis C Virus (HCV) exposure
简单的家庭测试,可快速、准确地筛查丙型肝炎病毒 (HCV) 暴露
- 批准号:
10709130 - 财政年份:2022
- 资助金额:
$ 16.35万 - 项目类别:
Workshop for the development of a Controlled Human Infection Model (CHIM) for hepatitis C virus (HCV) infection
丙型肝炎病毒(HCV)感染的受控人类感染模型(CHIM)开发研讨会
- 批准号:
460792 - 财政年份:2022
- 资助金额:
$ 16.35万 - 项目类别:
Miscellaneous Programs
Rapid, Point-of-Care Diagnostics for Hepatitis C Virus
丙型肝炎病毒的快速护理点诊断
- 批准号:
10683045 - 财政年份:2022
- 资助金额:
$ 16.35万 - 项目类别:
Perinatal care as a venue to reduce opioid overdoses and hepatitis C virus incidence (PreVenT OD HCV)
围产期护理是减少阿片类药物过量和丙型肝炎病毒发病率 (PreVenT OD HCV) 的场所
- 批准号:
10620846 - 财政年份:2022
- 资助金额:
$ 16.35万 - 项目类别:
A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV)
直接作用抗病毒药物预防丙型肝炎病毒感染供者肾移植至未感染受者的随机对照试验 (PREVENT-HCV)
- 批准号:
10597168 - 财政年份:2022
- 资助金额:
$ 16.35万 - 项目类别:
Characterization of key aspects of a controlled human infection model (CHIM) for hepatitis C virus (HCV) infection
丙型肝炎病毒 (HCV) 感染受控人类感染模型 (CHIM) 关键方面的表征
- 批准号:
472508 - 财政年份:2022
- 资助金额:
$ 16.35万 - 项目类别:
Operating Grants